MM Biotech develops AI-enabled R&D infrastructure for natural polysaccharides and the microbiome. Through AI4Glyco, proprietary polysaccharide resource databases, high-fidelity SynCom validation and standardized industrial delivery, we support B2B partners from candidate screening and validation through commercialization.
The team combines scientific advisory, platform strategy, R&D execution and operational delivery across the full translation path.
Scientific AdvisorProvides guidance across health sciences, TCM translation and Macau innovation resources.
Chief ScientistConnects platform strategy, serial entrepreneurship experience and listed-company advisory resources for industrial translation.
Scientific AdvisorProvides scientific guidance across polysaccharide research, drug discovery resources and functional translation.
Drives AI4Glyco platform strategy, industrial collaboration and B2B commercialization across research, productization and client delivery.
Supports company operations, project coordination, external resources and delivery workflows.
Supports polysaccharide-microbiome technology systems, data organization, validation workflows and project execution.
Coordinates R&D programs, polysaccharide resource organization, experimental collaboration and technical delivery.
Company development continues across University of Macau incubation, platform capability building, product translation and Hengqin-Macau industrial collaboration.
2024.08Built the company foundation for AI, polysaccharide science and microbiome innovation within the University of Macau and Hengqin-Macau innovation corridor.
2024-2025Entered entrepreneurship, big health acceleration, university-industry incubation and enterprise R&D support programs in Macau.
2025.04Continued to convert AI4Glyco platform capabilities into software assets for future SaaS/DaaS and reporting systems.
2025.05Extended polysaccharide function research into functional skincare, validating ingredient screening, formulation and commercialization expression.
2025.12Expanded into the Greater Bay Area innovation network while preparing follow-up innovation program resources.
2026.01Completed the Hengqin company setup and signed a collaboration agreement with Shanghai Sine Microecology.
2026.03-06Advanced Hengqin major R&D projects, probiotic and multinational ingredient collaborations, and the Qin Research Institute Voyage Program.
2028-2029Plans to deepen access to Macau innovation funds, technology park resources and Hengqin-Macau industrial collaboration.
MM Biotech is a representative company incubated by the University of Macau, aligned with Macau's economic diversification, AI high-tech development and traditional Chinese medicine / big health strategy.
Built from the University of Macau Innovation and Entrepreneurship Centre and Macau technology park ecosystem.
Uses AI4Glyco to translate Macau's polysaccharide, microbiome and TCM resources into industrial R&D capabilities.
Continues to connect with Macau innovation funds, technology park space and Hengqin-Macau industrial resources.
Selected records reflecting the company's R&D and intellectual-property development. Ownership, scope and validity are subject to the corresponding official documents.
The collaboration network spans industrial translation, clinical resources and research institutions, supporting AI4Glyco from underlying science to product delivery.
Covers polysaccharide ingredients, probiotics, synthetic biology, equipment platforms, functional food and industrial translation ecosystems.
Connects TCM hospitals, integrated hospitals and regional clinical resources for efficacy validation and translational pathways.
Deepens platform capabilities through University of Macau, TCM quality research, microbiology, drug discovery and Greater Bay Area university networks.
Documented laboratory, partnership and product-development scenes show how platform capabilities move from research into practical delivery.
